IDiyas

For the Inventor, By the Inventor

Valby, Denmark

Lisbet Kværnø

USPTO Granted Patents = 10 

Average Co-Inventor Count = 4.3

ph-index = 7

Forward Citations = 90(Granted Patents)


Company Filing History:

goldMedal10 out of 506 
 
H. Lundbeck A/s
 patents

Years Active: 2020-2025

Loading Chart...
10 patents (USPTO):Explore Patents
1. 12421271 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR, 10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2025-09-23),
2. 12384765 - Catecholamine prodrugs for use in the treatment of Parkinson's Disease (2025-08-12),
3. 12226428 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2025-02-18),
4. 11858954 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2024-01-02),
5. 11827665 - Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2023-11-28),
6. 11707476 - Catecholamine prodrugs for use in the treatment of parkinson's disease (2023-07-25),
7. 11130775 - Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2021-09-28),
8. 11110110 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2021-09-07),
9. 11104697 - Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid (2021-08-31),
10. 10729710 - Catecholamine prodrugs for use in the treatment of Parkinson's disease (2020-08-04),

Title: Innovations by Lisbet Kværnø

Introduction

Lisbet Kværnø is a prominent inventor based in Valby, Denmark. She has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds for treating neurodegenerative diseases. With a total of 10 patents to her name, her work is recognized for its potential impact on medical treatments.

Latest Patents

Among her latest patents is a groundbreaking invention related to solid forms of the compound (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid. This compound serves as a prodrug of a catecholamine, aimed at treating neurodegenerative diseases such as Parkinson's Disease. Additionally, her patent includes pharmaceutical compositions and methods for treating neurodegenerative or neuropsychiatric disorders using these innovative compounds.

Career Highlights

Lisbet Kværnø is currently employed at H. Lundbeck A/S, a leading pharmaceutical company known for its focus on brain diseases. Her work at Lundbeck has allowed her to advance her research and contribute to the development of new therapeutic options for patients suffering from debilitating conditions.

Collaborations

Throughout her career, Lisbet has collaborated with notable colleagues, including Martin Juhl and Klaus Gjervig Jensen. These partnerships have fostered a collaborative environment that enhances innovation and research in the pharmaceutical field.

Conclusion

Lisbet Kværnø's contributions to the field of pharmaceuticals, particularly in the treatment of neurodegenerative diseases, highlight her role as a leading inventor. Her innovative patents and collaborations continue to pave the way for advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…